Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

被引：6
|
作者：
Pal, Sumanta K. [2 ]
Lewis, Brian [3 ]
Sartor, Oliver [1 ,3 ,4 ]
机构：
[1] Tulane Med Sch, Tulane Canc Ctr, New Orleans, LA 70112 USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
[3] Tulane Univ Sch Med, Dept Med, New Orleans, LA 70112 USA
[4] Tulane Univ Sch Med, Dept Urol, New Orleans, LA 70112 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期
关键词：
Sipuleucel-T; Cabazitaxel; Abiraterone; mCRPC; PHASE-III TRIAL; MITOXANTRONE PLUS PREDNISONE; BONE METASTASES; CARCINOMA; MULTICENTER; EFFICACY; ANTIANDROGEN; CHEMOTHERAPY; PALLIATION; RADIUM-223;
D O I：
10.1016/j.ucl.2012.07.013
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The treatment of metastatic castration-resistant prostate cancer has evolved since the approval of docetaxel-based therapy. Since docetaxel approval, three new agents have gained approval for this indication: sipuleucel-T, cabazitaxel, and abiraterone. Recent Phase III trials have also demonstrated survival benefits for MDV-3100 and radium-223 though regulatory approval ispending. Practicing physicians face the challenge of determining the optimal sequencing of these new agents. This dilemma is particularly relevant to the post-docetaxel setting, in which the indication for several of these agents overlaps. This article details the efficacy and safety of these agents to provide a framework for their clinical use.
引用
收藏
页码：583 / +
页数：10
相关论文
共 50 条
  • [1] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [2] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (05) : 1040 - 1041
  • [3] Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
    Cornford, Philip
    [J]. JOURNAL OF CLINICAL UROLOGY, 2010, 3 (06) : 225 - 230
  • [4] Bevacizumab andWeekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
    Francini, Filippo
    Pascucci, Alessandra
    Francini, Edoardo
    Bargagli, Gianluca
    Conca, Raffaele
    Licchetta, Antonella
    Roviello, Giandomenico
    Martellucci, Ignazio
    Chiriaco, Giorgio
    Miano, Salvatora Tindara
    Marzocca, Giuseppe
    Manganelli, Antonio
    Ponchietti, Roberto
    Savelli, Vinno
    Petrioli, Roberto
    [J]. PROSTATE CANCER, 2011, 2011
  • [5] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    [J]. APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [6] Olaparib in metastatic castrate-resistant prostate cancer
    不详
    [J]. BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
  • [7] Metastatic castrate-resistant prostate cancer: dawn of a new age of management
    Masson, Susan
    Bahl, Amit
    [J]. BJU INTERNATIONAL, 2012, 110 (08) : 1110 - 1114
  • [8] Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.
    Shepard, D. R.
    Weil, A.
    Garcia, J. A.
    Dreicer, R.
    Raghavan, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Metastatic castrate-resistant prostate cancer, dawn of a new age of management
    Nemr, Elie G.
    [J]. BJU INTERNATIONAL, 2013, 111 (03) : E9 - E10
12345